Barcelona, Spain
July 6, 2002
This symposium presented vital information about the potentially beneficial effects of recombinant human growth hormone (rhGH) in improving outcome, adherence, and quality of life in patients with HIV/AIDS. Emerging data previewed the pathophysiology of HIV/AIDS adipose redistribution syndrome (HARS), HIV-associated wasting and lipodystrophy. Available data on the use of rhGH in HARS and HIV-associated wasting was discussed, as was the effect of rhGH on immune reconstitution in patients with HIV/AIDS.
OBJECTIVES
At the conclusion of the conference, the participant was able to:
- Understand the patient's concerns about wasting and lipodystrophy in the HAART era
- Understand growth hormone dynamics in HIV-related lipodystrophy.
- Identify the effects of growth hormone therapy on immune function in HIV-1 infected adults.
- Evaluate the role of Growth Hormone in lipodystrophy and HIV-associated wasting.
- Describe the pathophysiology and treatment of HIV-associated wasting in the era of HAART.
This course is accredited by the European Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists, www.uems.be.
Long-term Challenges of HAART: The Patient's Concerns is designated for a maximum of 2 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. EACCME credits are recognized as Physician’s Recognition Award by the American Medical Association.
The Royal College of Physicians, London, UK, has accredited this program with 2 credit hours (Reference number: 15807).
The Catalan Council on Continuing Medical Education and the Spanish Commission on Continuing Education for Health Professionals have accredited this CME activity with 0.4 credits (equivalent to 2.0 hours).
